Acute and Chronic Insomnia Treatment Market in 7MM Epidemiology Forecast to 2023

DALLAS, March 6, 2015 /PRNewswire/ --

ReportsnReports.com offers EpiCast Report: Insomnia - Epidemiology Forecast to 2023 report to its store. The report provides an overview of the risk factors, comorbidities and the global and historical trends for insomnia in the seven major markets (7MM).

Epidemiologists forecast that the total prevalent cases of acute insomnia in the 7MM will increase from 121,799,911 total prevalent cases in 2013, to 130,482,156 total prevalent cases in 2023 at an Annual Growth Rate (AGR) of 0.71%. GlobalData epidemiologists forecast an increase in the total prevalent cases of chronic insomnia (not fulfilling DSM-IV criteria) in the 7MM from 62,982,390 total prevalent cases in 2013, to 67,471,957 total prevalent cases in 2023 at an AGR of 0.71%. The 7MM had an estimated 23,690,040 total prevalent cases of chronic primary insomnia in 2013 and the number of total prevalent cases is expected to increase to 25,378,728 by 2023, at an AGR of 0.71%. GlobalData epidemiologists forecast that the total prevalent cases of chronic secondary insomnia in the 7MM will increase from 53,697,425 total prevalent cases in 2013, to 57,525,122 total prevalent cases in 2023 at an AGR of 0.71%. Complete report with TOC is available @ http://www.reportsnreports.com/reports/344994-epicast-report-insomnia-epidemiology-forecast-to-2023.html .

Insomnia is a highly prevalent condition; approximately one third of the general population presents with some degree of insomnia. Epidemiologists used comprehensive country-specific data from population-based studies published in peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia in the 7MM, based on the DSM-IV criteria. For all the 7MM, the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia were segmented by age and sex, which facilitates an understanding of the distribution of the disease within the population and informs strategies to improve the management of the disease. Furthermore, the forecast methodology is consistent across each of the 7MM, thereby allowing for a meaningful comparison of the forecast total prevalent cases among each market. Order a Purchase copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=344994 . (This is a premium report priced at US$3995 for a single user License.)

Scope of this report cover: The Insomnia EpiCast Report providess an overview of the risk factors, comorbidities, and the global and historical trends for insomnia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia, segmented by sex and age (in 15-year age groups beginning at 15 years and ending at =75 years) in these markets. The insomnia epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy 

• Develop business strategies by understanding the trends shaping and driving the global insomnia market.
• Quantify patient populations in the global insomnia market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for insomnia therapeutics in each of the markets covered.

Explore more reports of Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

Other Related Reports

Sleep Apnea - Pipeline Review, H2 2014

This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. Companies discussed in this report include Cortex Pharmaceuticals, Inc., Galleon Pharmaceuticals, Rottapharm SpA, SK Biopharmaceuticals Co., Ltd.

Obstructive Sleep Apnea Global Clinical Trials Review, H2, 2014

This report provides elemental information and data relating to the clinical trials on Obstructive Sleep Apnea. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Obstructive Sleep Apnea. Companies discussed in this report include Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Phillips Respironics International Inc., Cortex Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Chemical Holdings Corporation, Fisher & Paykel Healthcare Corporation Limited and BIOPROJET SCR.

About Us:
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
[email protected]

Connect with Us:

G+ / Google Plus:https://plus.google.com/u/0/111656568937629536321/posts 
Twitter:http://twitter.com/marketsreports 
Facebook:https://www.facebook.com/pages/ReportsnReports/191441427571689 
RSS / Feeds:http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE RnR Market Research